Clinical effectiveness of symptomatic therapy compared to standard step up care for the treatment of low impact psoriatic oligoarthritis: the 2-arm parallel group randomised POISE feasibility study
<p><strong>Introduction</strong> In psoriatic arthritis (PsA), treatment recommendations support first line use of disease-modifying anti-rheumatic drugs (DMARDs). There are few treatment strategy trials and no previous studies have investigated tailored treatment choice by disease...
| 主要な著者: | , , , , , , , , |
|---|---|
| フォーマット: | Journal article |
| 言語: | English |
| 出版事項: |
SAGE Publications
2022
|
| _version_ | 1826301982732713984 |
|---|---|
| author | Rombach, I Tucker, L Tillett, W Jadon, D Watson, M Francis, A Sinomati, Y Dutton, SJ Coates, L |
| author_facet | Rombach, I Tucker, L Tillett, W Jadon, D Watson, M Francis, A Sinomati, Y Dutton, SJ Coates, L |
| author_sort | Rombach, I |
| collection | OXFORD |
| description | <p><strong>Introduction</strong>
In psoriatic arthritis (PsA), treatment recommendations support first line use of disease-modifying anti-rheumatic drugs (DMARDs). There are few treatment strategy trials and no previous studies have investigated tailored treatment choice by disease severity. Studies in oligoarthritis (<5 inflamed joints) are limited but have suggested that some can be managed without DMARDs, preventing unnecessary side effects. This study aimed to assess the feasibility and acceptability of a study comparing standard DMARD treatment against symptomatic therapy in patients with mild psoriatic oligoarthritis.</p>
<p><strong>Methods</strong>
This trial was embedded within the MONITOR-PsA cohort, which uses a Trials Within Cohorts (TWiCs) design. Patients with newly diagnosed psoriatic oligoarthritis, with low disease activity (PASDAS ≤3.2) and the absence of poor prognostic factors (CRP<5mg/dL, HAQ <1, no radiographic erosions) were randomised open-label to either standard care with ‘step up’ DMARD therapy or to symptomatic therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and local corticosteroid injections to inflamed joints. Key outcomes were the proportion of eligible cohort patients, consent and study completion rate.</p>
<p><strong>Results</strong>
Over the 15-month study period, only 1 eligible patient was randomised. Although oligoarthritis patients represented 45% of patients in this early PsA cohort, the majority did not have mild disease (24% raised CRP, 51% moderate disease activity, 13% radiographic damage and/or poor function). Of those meeting trial inclusion criteria, many patients refused treatment in the observational cohort prior to an invitation into the trial as they did not wish to be treated with DMARDs.</p>
<p><strong>Conclusion</strong>
The study was not feasible as designed. Oligoarthritis represents around half of initial PsA presentations, but the majority starting therapy have high impact disease. A small proportion have mild oligoarticular disease but many are not keen on treatment with DMARDs, given the potential side effects of these medications. Further research is needed to support evidence-based treatment in this subgroup.</p>
|
| first_indexed | 2024-03-07T05:40:37Z |
| format | Journal article |
| id | oxford-uuid:e571d8b2-7a1f-41dd-9b4a-a2e9c2f8223c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:40:37Z |
| publishDate | 2022 |
| publisher | SAGE Publications |
| record_format | dspace |
| spelling | oxford-uuid:e571d8b2-7a1f-41dd-9b4a-a2e9c2f8223c2022-03-27T10:24:02ZClinical effectiveness of symptomatic therapy compared to standard step up care for the treatment of low impact psoriatic oligoarthritis: the 2-arm parallel group randomised POISE feasibility studyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:e571d8b2-7a1f-41dd-9b4a-a2e9c2f8223cEnglishSymplectic ElementsSAGE Publications2022Rombach, ITucker, LTillett, WJadon, DWatson, MFrancis, ASinomati, YDutton, SJCoates, L<p><strong>Introduction</strong> In psoriatic arthritis (PsA), treatment recommendations support first line use of disease-modifying anti-rheumatic drugs (DMARDs). There are few treatment strategy trials and no previous studies have investigated tailored treatment choice by disease severity. Studies in oligoarthritis (<5 inflamed joints) are limited but have suggested that some can be managed without DMARDs, preventing unnecessary side effects. This study aimed to assess the feasibility and acceptability of a study comparing standard DMARD treatment against symptomatic therapy in patients with mild psoriatic oligoarthritis.</p> <p><strong>Methods</strong> This trial was embedded within the MONITOR-PsA cohort, which uses a Trials Within Cohorts (TWiCs) design. Patients with newly diagnosed psoriatic oligoarthritis, with low disease activity (PASDAS ≤3.2) and the absence of poor prognostic factors (CRP<5mg/dL, HAQ <1, no radiographic erosions) were randomised open-label to either standard care with ‘step up’ DMARD therapy or to symptomatic therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and local corticosteroid injections to inflamed joints. Key outcomes were the proportion of eligible cohort patients, consent and study completion rate.</p> <p><strong>Results</strong> Over the 15-month study period, only 1 eligible patient was randomised. Although oligoarthritis patients represented 45% of patients in this early PsA cohort, the majority did not have mild disease (24% raised CRP, 51% moderate disease activity, 13% radiographic damage and/or poor function). Of those meeting trial inclusion criteria, many patients refused treatment in the observational cohort prior to an invitation into the trial as they did not wish to be treated with DMARDs.</p> <p><strong>Conclusion</strong> The study was not feasible as designed. Oligoarthritis represents around half of initial PsA presentations, but the majority starting therapy have high impact disease. A small proportion have mild oligoarticular disease but many are not keen on treatment with DMARDs, given the potential side effects of these medications. Further research is needed to support evidence-based treatment in this subgroup.</p> |
| spellingShingle | Rombach, I Tucker, L Tillett, W Jadon, D Watson, M Francis, A Sinomati, Y Dutton, SJ Coates, L Clinical effectiveness of symptomatic therapy compared to standard step up care for the treatment of low impact psoriatic oligoarthritis: the 2-arm parallel group randomised POISE feasibility study |
| title | Clinical effectiveness of symptomatic therapy compared to standard step up care for the treatment of low impact psoriatic oligoarthritis: the 2-arm parallel group randomised POISE feasibility study |
| title_full | Clinical effectiveness of symptomatic therapy compared to standard step up care for the treatment of low impact psoriatic oligoarthritis: the 2-arm parallel group randomised POISE feasibility study |
| title_fullStr | Clinical effectiveness of symptomatic therapy compared to standard step up care for the treatment of low impact psoriatic oligoarthritis: the 2-arm parallel group randomised POISE feasibility study |
| title_full_unstemmed | Clinical effectiveness of symptomatic therapy compared to standard step up care for the treatment of low impact psoriatic oligoarthritis: the 2-arm parallel group randomised POISE feasibility study |
| title_short | Clinical effectiveness of symptomatic therapy compared to standard step up care for the treatment of low impact psoriatic oligoarthritis: the 2-arm parallel group randomised POISE feasibility study |
| title_sort | clinical effectiveness of symptomatic therapy compared to standard step up care for the treatment of low impact psoriatic oligoarthritis the 2 arm parallel group randomised poise feasibility study |
| work_keys_str_mv | AT rombachi clinicaleffectivenessofsymptomatictherapycomparedtostandardstepupcareforthetreatmentoflowimpactpsoriaticoligoarthritisthe2armparallelgrouprandomisedpoisefeasibilitystudy AT tuckerl clinicaleffectivenessofsymptomatictherapycomparedtostandardstepupcareforthetreatmentoflowimpactpsoriaticoligoarthritisthe2armparallelgrouprandomisedpoisefeasibilitystudy AT tillettw clinicaleffectivenessofsymptomatictherapycomparedtostandardstepupcareforthetreatmentoflowimpactpsoriaticoligoarthritisthe2armparallelgrouprandomisedpoisefeasibilitystudy AT jadond clinicaleffectivenessofsymptomatictherapycomparedtostandardstepupcareforthetreatmentoflowimpactpsoriaticoligoarthritisthe2armparallelgrouprandomisedpoisefeasibilitystudy AT watsonm clinicaleffectivenessofsymptomatictherapycomparedtostandardstepupcareforthetreatmentoflowimpactpsoriaticoligoarthritisthe2armparallelgrouprandomisedpoisefeasibilitystudy AT francisa clinicaleffectivenessofsymptomatictherapycomparedtostandardstepupcareforthetreatmentoflowimpactpsoriaticoligoarthritisthe2armparallelgrouprandomisedpoisefeasibilitystudy AT sinomatiy clinicaleffectivenessofsymptomatictherapycomparedtostandardstepupcareforthetreatmentoflowimpactpsoriaticoligoarthritisthe2armparallelgrouprandomisedpoisefeasibilitystudy AT duttonsj clinicaleffectivenessofsymptomatictherapycomparedtostandardstepupcareforthetreatmentoflowimpactpsoriaticoligoarthritisthe2armparallelgrouprandomisedpoisefeasibilitystudy AT coatesl clinicaleffectivenessofsymptomatictherapycomparedtostandardstepupcareforthetreatmentoflowimpactpsoriaticoligoarthritisthe2armparallelgrouprandomisedpoisefeasibilitystudy |